You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: June 18, 2025

Details for Patent: 10,213,512


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,213,512
Title:Topical tetracycline compositions
Abstract: A topical therapeutic hydrophobic breakable composition includes a carrier comprising (a) about 60% to about 99% by weight of at least one hydrophobic oil; (b) at least one viscosity-modifying agents selected from the group consisting of a fatty alcohol, a fatty acid and a wax; and (c) a tetracycline antibiotic, characterized in that at least part of the tetracycline antibiotic is suspended in the composition; the viscosity of the composition is at least about 30% higher than the viscosity of the carrier without the tetracycline antibiotic; and is higher than the viscosity of the hydrophobic oil and the tetracycline antibiotic without the viscosity modifying agents. The tetracycline is chemically stable in the composition for at least six months; wherein more than about 90% of the tetracycline has not broken down. The composition is packaged as a breakable foam that breaks easily upon application of shear force.
Inventor(s): Tamarkin; Dov (Maccabim, IL), Gazal; Elana (Rehovot, IL), Papiashvili; Irakliy (Ashkelon, IL), Hazot; Yohan (Rehovot, IL), Schuz; David (Gimzu, IL), Keynan; Rita (Rehovot, IL)
Assignee: FOAMIX PHARMACEUTICALS LTD. (Rehovot, IL)
Application Number:15/591,733
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 10,213,512
Patent Claim Types:
see list of patent claims
Use; Composition;
Patent landscape, scope, and claims:

Understanding the Scope and Claims of United States Patent 10,213,512

Introduction to Patent 10,213,512

United States Patent 10,213,512, assigned to Foamix Pharmaceuticals Ltd., is a significant patent in the pharmaceutical industry, particularly protecting the drugs AMZEEQ and ZILXI. This patent is part of a larger family of patents with international coverage, highlighting its global importance.

Patent Overview

  • Assignee: Foamix Pharmaceuticals Ltd. (Rehovot, IL)
  • Inventors: Dov Tamarkin, Elana Gazal, Irakliy Papiashvili, Yohan Hazot, David Schuz, and Rita Keynan
  • Application Number: 15/591,733
  • Patent Claim Types: Use and Composition claims[1].

Protected Drugs: AMZEEQ and ZILXI

  • AMZEEQ: This is a topical minocycline foam used for the treatment of moderate to severe acne vulgaris in adults and pediatric patients 9 years of age and older.
  • ZILXI: This is a topical minocycline foam indicated for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in adults[1].

International Patent Coverage

The patent has twenty-two patent family members in ten countries, including Australia, Brazil, and Canada, ensuring broad international protection for the inventions covered by this patent[1].

Patent Claims and Scope

Claim Types

The patent includes both use and composition claims. Use claims define the specific uses of the invention, while composition claims define the chemical or physical composition of the invention.

Independent Claim Length and Count

Research on patent scope suggests that the length and count of independent claims can be metrics for measuring patent scope. Patents with narrower claims, as indicated by shorter independent claim lengths and fewer independent claims, are often associated with a higher probability of grant and a shorter examination process[3].

Determining Inventorship

Importance of Correct Inventorship

In the United States, determining the true and only inventors is crucial for the validity of a patent. The conception of the idea or subject matter of the patent claims is a key factor in identifying inventors. Conception is defined as the formation in the mind of the inventor of a definite and permanent idea of the complete and operative invention[2].

Consequences of Incorrect Inventorship

Incorrectly naming inventors can lead to a patent being declared invalid. Deceptive intent in naming inventors can render the patent unenforceable, even if the correct inventorship is later established[2].

Patent Litigation and PTAB Cases

Patent 10,213,512 may be involved in various patent litigation and PTAB (Patent Trial and Appeal Board) cases, which can impact its validity and enforceability. These cases often revolve around disputes over inventorship, claim scope, and patent infringement[1].

Patent Expiration and Supplementary Protection Certificates

The patent's expiration date varies by country, with supplementary protection certificates (SPCs) potentially extending the protection period in certain jurisdictions. For example, in Australia, the estimated expiration dates for related patents are available upon subscription to specific services[1].

Economic and Innovation Impact

Patenting Trends

Patents like 10,213,512 are indicators of technological innovation and economic activity. The U.S. patenting system provides exclusive rights to inventors, encouraging innovation by protecting their inventions from unauthorized use[4].

Global Trends

The global landscape of patenting shows that patents are crucial for knowledge transfer and innovation. The U.S. Patent and Trademark Office (USPTO) data provide insights into patenting trends, including the technological areas where patents are most frequently granted[4].

Regulatory Framework

The USPTO is the agency responsible for granting U.S. patents and registering trademarks. The process involves rigorous examination to ensure that patents meet the criteria of being novel, nonobvious, and sufficiently useful[5].

Key Takeaways

  • Patent Coverage: Protects AMZEEQ and ZILXI, with international coverage in multiple countries.
  • Claim Types: Includes use and composition claims.
  • Inventorship: Correct determination of inventors is crucial for patent validity.
  • Patent Scope: Narrower claims are associated with higher grant probabilities and shorter examination processes.
  • Economic Impact: Patents like 10,213,512 drive innovation and economic activity.
  • Regulatory Framework: The USPTO ensures that patents meet strict criteria before grant.

FAQs

Q: What drugs are protected by United States Patent 10,213,512? A: The patent protects AMZEEQ and ZILXI, both topical minocycline foams used for treating acne.

Q: Why is correct inventorship important for a patent? A: Correct inventorship is crucial because incorrect naming of inventors can lead to the patent being declared invalid or unenforceable.

Q: How does the length and count of independent claims affect patent scope? A: Patents with narrower claims, indicated by shorter independent claim lengths and fewer independent claims, are often associated with a higher probability of grant and a shorter examination process.

Q: What is the role of the USPTO in the patent process? A: The USPTO is responsible for granting U.S. patents and registering trademarks, ensuring that patents meet the criteria of being novel, nonobvious, and sufficiently useful.

Q: How does patent 10,213,512 contribute to global innovation trends? A: By protecting innovative pharmaceutical products, the patent encourages further innovation and knowledge transfer in the pharmaceutical industry.

Sources

  1. Drug Patent Watch: "Patent 10,213,512" - https://www.drugpatentwatch.com/p/patent/10213512
  2. Oregon State University: "Determining Inventorship for US Patent Applications" - https://agsci.oregonstate.edu/sites/agsci/files/main/research/vrc_release_inventorship-gattari.pdf
  3. SSRN: "Patent Claims and Patent Scope" - https://papers.ssrn.com/sol3/papers.cfm?abstract_id=2844964
  4. NSF: "Invention: U.S. and Comparative Global Trends" - https://ncses.nsf.gov/pubs/nsb20204/invention-u-s-and-comparative-global-trends
  5. USA.gov: "U.S. Patent and Trademark Office (USPTO)" - https://www.usa.gov/agencies/u-s-patent-and-trademark-office

More… ↓

⤷  Try for Free


Drugs Protected by US Patent 10,213,512

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Journey AMZEEQ minocycline hydrochloride AEROSOL, FOAM;TOPICAL 212379-001 Oct 18, 2019 RX Yes Yes ⤷  Try for Free ⤷  Try for Free Y TREATMENT OF NON-NODULAR ACNE VULGARIS ⤷  Try for Free
Journey ZILXI minocycline hydrochloride AEROSOL, FOAM;TOPICAL 213690-001 May 28, 2020 RX Yes Yes ⤷  Try for Free ⤷  Try for Free Y TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.